Adjuvant Trastuzumab Deruxtecan Versus Trastuzumab Emtansine by Residual Cancer Burden in HER2-Positive Early Breast Cancer: A Decision Analysis
Decision modeling to project 10-year survival across recurrence-risk groups to aid in clinical decision-making favors T-DXd for patients with RCB-II or RCB-III disease, and for RCB-I patients, particularly those with ER-positive tumors, the projected survival gain is smaller and sensitive to fatal ILD assumptions.